ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

MRKR Marker Therapeutics Inc

4.11
0.06 (1.48%)
Fuera de horario
Última actualización: 15:00:05
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Marker Therapeutics Inc MRKR NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.06 1.48% 4.11 15:00:05
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
4.05 4.05 4.27 4.11 4.05
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
08/4/202406:00GLOBEPrincipal Investigator from City of Hope National Medical..
25/3/202416:45GLOBEMarker Therapeutics Reports Year-End 2023 Corporate and..
22/3/202411:30GLOBEMarker Therapeutics to Present at the H.C. Wainwright 2nd..
01/3/202407:02EDGAR2Form 8-K - Current report
26/2/202406:58EDGAR2Form 8-K - Current report
22/1/202406:30GLOBEMarker Therapeutics Receives Approval from United States..
08/1/202407:30EDGAR2Form 8-K - Current report
08/1/202407:24GLOBEMarker Therapeutics Announces Clinical Program Updates and..
21/12/202310:00GLOBEMarker Therapeutics Announces Participation in Biotech..
11/12/202306:35EDGAR2Form 8-K - Current report
11/12/202306:00GLOBEMarker Therapeutics Announces Sustained Complete Response in..
20/11/202315:37EDGAR2Form 8-K - Current report
09/11/202316:03EDGAR2Form 8-K - Current report
09/11/202316:00GLOBEMarker Therapeutics Reports Third Quarter 2023 Financial..
09/11/202315:31EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/9/202306:10EDGAR2Form 8-K - Current report
11/9/202306:00GLOBEMarker Therapeutics Announces Complete Response in First..
30/8/202307:00GLOBEMarker Therapeutics to Present at the H.C. Wainwright 25th..
14/8/202315:37EDGAR2Form 8-K - Current report
14/8/202315:30GLOBEMarker Therapeutics Reports Second Quarter 2023 Financial..
14/8/202315:03EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/8/202306:22EDGAR2Form 8-K - Current report
07/8/202306:00GLOBEMarker Therapeutics Reports Non-Clinical Proof-of-Concept..
26/7/202306:00GLOBEMarker Therapeutics to Participate in Virtual Roundtable..
10/7/202306:09EDGAR2Form 8-K - Current report
10/7/202306:00GLOBEEuropean Medicines Agency Grants Orphan Drug Designation for..
05/7/202315:22EDGAR2Form 3 - Initial statement of beneficial ownership of..
03/7/202315:05EDGAR2Form 8-K - Current report
30/6/202315:05EDGAR2Form 8-K - Current report
26/6/202306:00GLOBEMarker Therapeutics Reports MT-401 Non-Clinical Data in AML..
12/6/202306:00GLOBEMarker Therapeutics Announces First Lymphoma Patient Treated..
31/5/202305:30GLOBEMarker Therapeutics Reports Pre-Clinical Data of its MT-601..
08/5/202306:30GLOBEMarker Therapeutics Appoints Monic Stuart, M.D., as Chief..

Su Consulta Reciente

Delayed Upgrade Clock